CRISPR/cas systems redefine nucleic acid detection: Principles and methods

被引:189
作者
Wang, Meng [1 ,2 ,3 ]
Zhang, Rui [1 ,2 ,3 ]
Li, Jinming [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Beijing Hosp, Natl Ctr Clin Labs, Natl Ctr Gerontol,Inst Geriatr Med, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll, Grad Sch, Beijing, Peoples R China
[3] Beijing Hosp, Beijing Engn Res Ctr Lab Med, Beijing, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
CRISPR; Nucleic acid detection; Biosensing assays; Imaging assays; DNA sequencing; GENOME-WIDE ANALYSIS; IN-SITU; TARGET-ENRICHMENT; RNA TRANSCRIPTS; GUIDE-RNA; CAS9; PLATFORM; COMPLEX; HYBRIDIZATION; SPECIFICITY;
D O I
10.1016/j.bios.2020.112430
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Methods that enable rapid, sensitive and specific analyses of nucleic acid sequences have positive effects on precise disease diagnostics and effective clinical treatments by providing direct insight into clinically relevant genetic information. Thus far, many CRISPR/Cas systems have been repurposed for diagnostic functions and are revolutionizing the accessibility of robust diagnostic tools due to their high flexibility, sensitivity and specificity. As RNA-guided targeted recognition effectors, Cas9 variants have been utilized for a variety of diagnostic applications, including biosensing assays, imaging assays and target enrichment for next-generation sequencing (NGS), thereby enabling the development of flexible and cost-effective tests. In addition, the ensuing discovery of Cas proteins (Cas12 and Cas13) with collateral cleavage activities has facilitated the development of numerous diagnostic tools for rapid and portable detection, and these tools have great potential for point-of-care settings. However, representative reviews proposed on this topic are mainly confined to classical biosensing applications; thus, a comprehensive and systematic description of this fast-developing field is required. In this review, based on the detection principle, we provide a detailed classification and comprehensive discussion of recent works that harness these CRISPR-based diagnostic tools from a new perspective. Furthermore, current challenges and future perspectives of CRISPR-based diagnostics are outlined.
引用
收藏
页数:18
相关论文
共 107 条
[1]   C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector [J].
Abudayyeh, Omar O. ;
Gootenberg, Jonathan S. ;
Konermann, Silvana ;
Joung, Julia ;
Slaymaker, Ian M. ;
Cox, David B. T. ;
Shmakov, Sergey ;
Makarova, Kira S. ;
Semenova, Ekaterina ;
Minakhin, Leonid ;
Severinov, Konstantin ;
Regev, Aviv ;
Lander, Eric S. ;
Koonin, Eugene V. ;
Zhang, Feng .
SCIENCE, 2016, 353 (6299)
[2]   Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review [J].
Adhikari, Sasmita Poudel ;
Meng, Sha ;
Wu, Yu-Ju ;
Mao, Yu-Ping ;
Ye, Rui-Xue ;
Wang, Qing-Zhi ;
Sun, Chang ;
Sylvia, Sean ;
Rozelle, Scott ;
Raat, Hein ;
Zhou, Huan .
INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
[3]   CRISPR off-target analysis in genetically engineered rats and mice [J].
Anderson, Keith R. ;
Haeussler, Maximilian ;
Watanabe, Colin ;
Janakiraman, Vasantharajan ;
Lund, Jessica ;
Modrusan, Zora ;
Stinson, Jeremy ;
Bei, Qixin ;
Buechler, Andrew ;
Yu, Charles ;
Thamminana, Sobha R. ;
Tam, Lucinda ;
Sowick, Michael-Anne ;
Alcantar, Tuija ;
O'Neil, Natasha ;
Li, Jinjie ;
Ta, Linda ;
Lima, Lisa ;
Roose-Girma, Merone ;
Rairdan, Xin ;
Durinck, Steffen ;
Warming, Soren .
NATURE METHODS, 2018, 15 (07) :512-+
[4]   Basic principles of real-time quantitative PCR [J].
Arya, M ;
Shergill, IS ;
Williamson, M ;
Gommersall, L ;
Arya, N ;
Patel, HRH .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2005, 5 (02) :209-219
[5]   Advances in clinical next-generation sequencing: target enrichment and sequencing technologies [J].
Ballester, Leomar Y. ;
Luthra, Rajyalakshmi ;
Kanagal-Shamanna, Rashmi ;
Singh, Rajesh R. .
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (03) :357-372
[6]   Next-Generation Sequencing in Oncology in the Era of Precision Medicine [J].
Blumenthal, Gideon M. ;
Mansfield, Elizabeth ;
Pazdur, Richard .
JAMA ONCOLOGY, 2016, 2 (01) :13-14
[7]   CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic Acid Amplification-Free miRNA Diagnostics [J].
Bruch, Richard ;
Baaske, Julia ;
Chatelle, Claire ;
Meirich, Mailin ;
Madlener, Sibylle ;
Weber, Wilfried ;
Dincer, Can ;
Urban, Gerald Anton .
ADVANCED MATERIALS, 2019, 31 (51)
[8]   Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis [J].
Bustin, SA ;
Mueller, R .
CLINICAL SCIENCE, 2005, 109 (04) :365-379
[9]   Minimal PAM specificity of a highly similar SpCas9 ortholog [J].
Chatterjee, Pranam ;
Jakimo, Noah ;
Jacobson, Joseph M. .
SCIENCE ADVANCES, 2018, 4 (10)
[10]   Precise Cas9 targeting enables genomic mutation prevention [J].
Chavez, Alejandro ;
Pruitt, Benjamin W. ;
Tuttle, Marcelle ;
Shapiro, Rebecca S. ;
Cecchi, Ryan J. ;
Winston, Jordan ;
Turczyk, Brian M. ;
Tung, Michael ;
Collins, James J. ;
Church, George M. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (14) :3669-3673